Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.


Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
02 2019
Historique:
received: 18 07 2018
revised: 15 10 2018
accepted: 27 10 2018
pubmed: 18 11 2018
medline: 29 10 2019
entrez: 17 11 2018
Statut: ppublish

Résumé

The objective was to compare different definitions of remission and low disease activity (LDA) in patients with psoriatic arthritis (PsA), based on both patients' and physicians' perspectives. In ReFlap (Remission/Flare in PsA; NCT03119805), adults with physician-confirmed PsA and >2 years of disease duration in 14 countries were included. Remission was defined as very low disease activity (VLDA), Disease Activity index for PSoriatic Arthritis (DAPSA) ≤4, and physician-perceived and patient-perceived remission (specific question yes/no), and LDA as minimal disease activity (MDA), DAPSA <14, and physician-perceived and patient-perceived LDA. Frequencies of these definitions, their agreement (prevalence-adjusted kappa), and sensitivity and specificity versus patient-defined status were assessed cross-sectionally. Of 410 patients, the mean age (SD) was 53.9 (12.5) years, 50.7% were male, disease duration was 11.2 (8.2) years, 56.8% were on biologics, and remission/LDA was frequently attained: respectively, for remission from 12.4% (VLDA) to 36.1% (physician-perceived remission), and for LDA from 25.4% (MDA) to 43.9% (patient-perceived LDA). Thus, patient-perceived remission/LDA was frequent (65.4%). Agreement between patient-perceived remission/LDA and composite scores was moderate to good (kappa range, 0.12-0.65). When patient-perceived remission or LDA status is used as reference, DAPSA-defined remission/LDA and VLDA/MDA had a sensitivity of 73.1% and 51.5%, respectively, and a specificity of 76.8% and 88.0%, respectively. Physician-perceived remission/LDA using a single question was frequent (67.6%) but performed poorly against other definitions. In this unselected population, remission/LDA was frequently attained. VLDA/MDA was a more stringent definition than DAPSA-based remission/LDA. DAPSA-based remission/LDA performed better than VLDA/MDA to detect patient-defined remission or remission/LDA. Further studies of long-term outcomes are needed.

Sections du résumé

BACKGROUND
The objective was to compare different definitions of remission and low disease activity (LDA) in patients with psoriatic arthritis (PsA), based on both patients' and physicians' perspectives.
METHODS
In ReFlap (Remission/Flare in PsA; NCT03119805), adults with physician-confirmed PsA and >2 years of disease duration in 14 countries were included. Remission was defined as very low disease activity (VLDA), Disease Activity index for PSoriatic Arthritis (DAPSA) ≤4, and physician-perceived and patient-perceived remission (specific question yes/no), and LDA as minimal disease activity (MDA), DAPSA <14, and physician-perceived and patient-perceived LDA. Frequencies of these definitions, their agreement (prevalence-adjusted kappa), and sensitivity and specificity versus patient-defined status were assessed cross-sectionally.
RESULTS
Of 410 patients, the mean age (SD) was 53.9 (12.5) years, 50.7% were male, disease duration was 11.2 (8.2) years, 56.8% were on biologics, and remission/LDA was frequently attained: respectively, for remission from 12.4% (VLDA) to 36.1% (physician-perceived remission), and for LDA from 25.4% (MDA) to 43.9% (patient-perceived LDA). Thus, patient-perceived remission/LDA was frequent (65.4%). Agreement between patient-perceived remission/LDA and composite scores was moderate to good (kappa range, 0.12-0.65). When patient-perceived remission or LDA status is used as reference, DAPSA-defined remission/LDA and VLDA/MDA had a sensitivity of 73.1% and 51.5%, respectively, and a specificity of 76.8% and 88.0%, respectively. Physician-perceived remission/LDA using a single question was frequent (67.6%) but performed poorly against other definitions.
CONCLUSION
In this unselected population, remission/LDA was frequently attained. VLDA/MDA was a more stringent definition than DAPSA-based remission/LDA. DAPSA-based remission/LDA performed better than VLDA/MDA to detect patient-defined remission or remission/LDA. Further studies of long-term outcomes are needed.

Identifiants

pubmed: 30442648
pii: annrheumdis-2018-214140
doi: 10.1136/annrheumdis-2018-214140
doi:

Substances chimiques

Antirheumatic Agents 0
Biological Products 0

Banques de données

ClinicalTrials.gov
['NCT03119805']

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

201-208

Subventions

Organisme : Department of Health
ID : CS-2016-16-016
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Clémence Gorlier (C)

Sorbonne Université, Paris, France.

Ana-Maria Orbai (AM)

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Déborah Puyraimond-Zemmour (D)

Sorbonne Université, Paris, France.

Laura C Coates (LC)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Uta Kiltz (U)

Rheumazentrum Ruhrgebiet, Herne and Ruhr-Universität, Bochum, Germany.

Ying-Ying Leung (YY)

Rheumatology Department, Singapore General Hospital, Singapore, Singapore.

Penelope Palominos (P)

Rheumatology Department, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.

Juan D Cañete (JD)

Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain.

Rossana Scrivo (R)

Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza Università di Roma, Rome, Italy.

Andra Balanescu (A)

Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.

Emmanuelle Dernis (E)

Rheumatology Department, Le Mans Central Hospital, Le Mans, France.

Sandra Tälli (S)

Rheumatology Department, Tallinn Central Hospital, Tallinn, Estonia.

Adeline Ruyssen-Witrand (A)

Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France.

Martin Soubrier (M)

Rheumatology Department, Gabriel Montpied Hospital, Clermont-Ferrand, France.

Sibel Zehra Aydin (SZ)

University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, Canada.

Lihi Eder (L)

Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.

Inna Gaydukova (I)

Rheumatology Department, North-Western State Medical University, St Petersburg, Russia.

Ennio Lubrano (E)

Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute 'Vincenzo Tiberio', University of Molise, Campobasso, Italy.

Umut Kalyoncu (U)

Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Pascal Richette (P)

Hopital Lariboisiere Centre Viggo Petersen, Service de Rhumatologie, Paris, France.
Universite Paris Diderot UFR de Medecine, Inserm UMR1132 Bioscar, Paris, France.

M Elaine Husni (ME)

Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio, USA.

Maarten de Wit (M)

Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, The Netherlands.

Josef S Smolen (JS)

Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria.

Laure Gossec (L)

Sorbonne Université, Paris, France laure.gossec@gmail.com.
Rheumatology Department, Pitié Salpêtrière Hospital, APHP, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH